Secondary leukemia with a translocation (8;21)?
The clinical features and cytogenetic changes of acute myeloid leukemia (AML) developing 10 years after radiotherapy and chemotherapy (for osteosarcoma) are described. Features of both de novo AML [FAB M2 morphology, t(8;21), and "secondary leukemia" (additional cytogenetic changes, resistance to chemotherapy) were present. The importance of differentiation between primary and "therapy-linked" disease, and the difficulties in making such a distinction, are discussed.
Davies
S V
SV
Department of Hematology, Selly Oak Hospital, Birmingham, Great Britain.
Murray
J A
JA
Bowser-Riley
S M
SM
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002891:Chromosomes, Human, Pair 21; D002898:Chromosomes, Human, Pair 8; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000209:etiology / Q000235:genetics*; D007953:Leukemia, Radiation-Induced / Q000235:genetics*; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D014178:Translocation, Genetic
D000970:Antineoplastic Agents